Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MSD Files Keytruda for RCC in Combo Therapy with Lenvima
April 13, 2021
- Maruho Aspires to Get Back on Growth Track on New Drug Launches: President
April 12, 2021
- Kobayashi Kako’s Seima Factory Operations Still Halted Even after 60-Day Order Lifted
April 12, 2021
- Daiichi Sankyo Kicks Off Japan PII for Pexidartinib for TGCT
April 12, 2021
- Drug Reps Increase Online Meetings in February amid Emergency: Intage
April 9, 2021
- Hisamitsu’s Sales Sag 18.8% on Price Cuts, Gx, COVID-19
April 9, 2021
- Nichi-Iko Recalls 2 Products over Quality Issues Days after Biz Suspension Lifted
April 9, 2021
- Daiichi Sankyo Kicks Off PI/II Study for Menin Inhibitor in AML/ALL
April 9, 2021
- Teijin Pharma Set to Transform Biz, Weather Feburic Patent Cliff with Takeda’s DPP-4s
April 8, 2021
- Astellas Ended Scholarship Donation to Clear Up Doubts on Inducing Prescriptions, No Major Issues Seen after 1 Year
April 8, 2021
- Japan Ethical Drug Sales Fall 2.8% in FY2020: Encise
April 8, 2021
- HUYA Files HBI-8000 for PTCL in Japan: Meiji
April 8, 2021
- Japan Ethical Drug Sales Down 3.8% in February: Crecon
April 8, 2021
- Shonan iPark Partners with UK Bioscience Hub
April 7, 2021
- Takeda Sees FY2021 as Inflection Year for Pipeline, 4 Potential Approvals from 6 Submission-Planned Assets
April 7, 2021
- AstraZeneca's COVID-19 Vaccine as Effective for UK Variant:Exec
April 7, 2021
- AstraZeneca Looks to Become Top Drug Maker in Japan by 2025
April 7, 2021
- Daiichi Sankyo Looks to Rack Up Sales of 1.6 Trillion Yen in FY2025, 3 ADCs as Drivers
April 6, 2021
- Astellas, Toa Eiyo to End Sales Collaboration in March 2022
April 6, 2021
- Kowa Seeks 5.6 Billion Yen in Add’l Damages from Towa over Livalo Generics
April 6, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…